A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)



Status:Active, not recruiting
Conditions:Lung Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/19/2018
Start Date:March 28, 2014
End Date:July 2, 2020

Use our guide to learn which trials are right for you!

A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in
combination with another anti-cancer drug in participants with NSCLC that is advanced or has
spread to other parts of the body (stage IV). The study will also investigate how the body
processes the combination treatment and how the study drug affects the body. The study will
also collect disease-related symptoms and participant-reported pain related to NSCLC.


Inclusion Criteria:

- For all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).

- For Part A (abemaciclib + pemetrexed): Non-squamous subtypes only. The participant
must have received at least one but no more than three prior therapies for
advanced/metastatic NSCLC.

- For Part B (abemaciclib + gemcitabine): Any subtype. The participant must have
received at least one but not more than three prior therapies for advanced/metastatic
NSCLC.

- For Part C (abemaciclib + ramucirumab): Any subtype. The participant must have
received at least two but not more than three prior therapies for advanced/metastatic
NSCLC.

- For Part D (abemaciclib + LY3023414): Any subtype. The participant must have received
at least two, but not more than three prior therapies for advanced/metastatic NSCLC.
The participant must not have received prior treatment with any phosphoinositide
3-kinase (PI3K) or mammalian target of rapamycin (mTOR) inhibitor.

- For Part E (abemaciclib + pembrolizumab): Any subtype. The participant must have
received at least one but no more than three prior therapies for advanced/metastatic
NSCLC.

- Have either measureable or nonmeasurable disease as defined by the Response Evaluation
Criteria in Solid Tumors (RECIST v1.1).

- Have adequate organ function including:

- Hematologic: Absolute neutrophil count (ANC) 1.5 x 109/liter (L), platelets 100 x
109/L, and hemoglobin 8 gram/deciliter (g/dL).

- Hepatic: Bilirubin 1.5 times upper limits of normal (ULN), alanine
aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For
participants with tumor involvement of the liver, AST and ALT equaling ≤5.0 times
ULN are acceptable. Alkaline phosphatase ≤5.0 times ULN for participants with
tumor involvement of the bone is acceptable.

- Renal: Serum creatinine 1.5 times ULN.

- Have a performance status ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.

- Have discontinued all previous therapies for cancer (including chemotherapy,
radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for
myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving
study drug, and recovered from the acute effects of therapy (treatment related
toxicity resolved to baseline) except for residual alopecia.

- Male and female participants of reproductive potential must agree to use medically
approved contraceptive precautions during the trial and 3 to 4 months (as appropriate)
following last dose of study drug.

- Have an estimated life expectancy of ≥12 weeks.

- Are able to swallow oral medications.

Exclusion Criteria:

- Have a personal history of any of the following conditions: presyncope or syncope of
either unexplained or cardiovascular etiology, ventricular arrhythmia (including but
not limited to ventricular tachycardia and ventricular fibrillation), or sudden
cardiac arrest. Exception: Participants with controlled atrial fibrillation for >30
days prior to study treatment are eligible.

- Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of
associated neurological changes 14 days prior to receiving study drug.

- Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
in-situ of the cervix or breast), unless in complete remission with no therapy for a
minimum of 3 years.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the pre-screening or screening visit
through 3 to 4 months after the last dose of trial treatment (as appropriate).

- Have active bacterial, fungal, and/or known viral infection (for example, human
immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or
hepatitis C antibodies). Screening is not required for enrollment.

- Parts A, B, C, and E: Have QTc interval of > 470 millisecond (msec) on screening
electrocardiogram (ECG). Part D participants have QTc interval of >450msec on
screening ECG.

Additional Exclusion Criteria For Part C

- History or evidence of cardiovascular risk including any of the following:

- History of acute coronary syndromes (including myocardial infarction and angina),
coronary angioplasty, or stenting within 6 months prior to enrollment.

- History or evidence of current ≥Class II congestive heart failure as defined by
New York Heart Association.

- Treatment refractory hypertension defined as a blood pressure of systolic >140
millimeter of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled
by antihypertensive therapy.

- Participants with intracardiac defibrillators.

- History or evidence of CNS disease. Radiographic screening of all participants without
history of CNS metastasis is required.

- Radiographically documented evidence of major vessel invasion or encasement by cancer.

- Uncontrolled thromboembolic or hemorrhagic disorders.

- Participants receiving daily treatment with aspirin >325mg/day or other known
inhibitors of platelet function.

- History of gross hemoptysis within 2 months of study entry.

- Evidence of nonhealing wounds, ulcers, or bone fractures within 28 days prior to study
entry.

- Undergone major surgery within 28 days prior to first dose of study drug or have
subcutaneous venous access device placement within 7 days prior to first dose.

Additional Exclusion Criteria For Part D

- Have insulin-dependent diabetes mellitus or a history of gestational diabetes
mellitus.

- Participants with a type 2 diabetes mellitus are eligible if adequate control of blood
glucose level is obtained by oral anti-diabetic agents as documented by hemoglobin A1c
(HbA1c) <7%.

- History or evidence of cardiovascular risk including any of the following -- History
of acute coronary syndromes (including myocardial infarction and angina), coronary
angioplasty, or stenting within 6 months prior to enrollment.

Additional Exclusion Criteria for Part E

- Received prior monoclonal antibody (mAb) within 4 weeks prior to study.

- Has active autoimmune disease that has required treatment in the past 2 years.

- Has history of interstitial lung disease or pneumonitis.
We found this trial at
9
sites
Germantown, Tennessee 38138
Principal Investigator: Daruka Mahadevan
Phone: 901-683-0055
?
mi
from
Germantown, TN
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Emrullah Yilmaz
Phone: 505-925-0403
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
Principal Investigator: Edward Kim
Phone: 980-442-3105
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
Principal Investigator: Eric Schaefer
Phone: 479-872-8130
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Martin Gutierrez
Phone: 551-996-5900
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Shadia Jalal
Phone: 317-274-4505
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Los Angeles, California 90095
Principal Investigator: Jonathan Goldman
Phone: 310-633-8400
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
km. 9,100 Carretera Colmenar Viejo
Madrid, 28034
Principal Investigator: Pilar Garrido López
Phone: 34913368263
?
mi
from
Madrid,
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Karen Kelly
Phone: 916-734-3735
?
mi
from
Sacramento, CA
Click here to add this to my saved trials